Zentiva acquires UK maker of generics

1 April 2019
zentiva-big

In a second acquisition this year, Czech Republic-based generics drugmaker Zentiva Group announced it has bought Creo Pharmaceuticals in the UK, a subsidiary of Amneal Pharmaceuticals (NYSE: AMRX).

Nick Haggar, chief executive of Zentiva stated: "Zentiva is delighted to confirm the acquisition of Creo Pharma which will strengthen Zentiva's position in the UK. This move reflects our confidence in the UK and our deep commitment to the development, manufacture and supply of high-quality affordable medicines. We welcome the Creo Pharma team who have a strong reputation for providing high-quality services to their customers."

Amneal’s shares moved up 1.13% to $14.33 soon after markets opened this morning.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics